NOV-110201

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNOV-110201
Drug Alias Nameanti-KDR antibody (National OncoVenture)NOV-110201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionVascular endothelial growth factor receptor 2 modulators
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Oncoventure
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Oncoventure
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A